
Halia Therapeutics
Halia Therapeutics is a clinical-stage biopharmaceutical company developing medicines for patients with serious diseases.
- 11
- Private company
- Lehi, UT, USUnited States

Halia Therapeutics is a clinical-stage biopharmaceutical company developing medicines for patients with serious diseases.
haliatx.comCrawled Oct 27, 2026
Halia Therapeutics develops therapies targeting genetic resilience in families, focusing on NLRP3 and inflammation-related chronic diseases.
Halia Therapeutics, a clinical-stage biopharmaceutical company, will attend the 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 Forum. The company focuses on developing first-in-class therapies targeting inflammasome-driven diseases. The event takes place October 13–14, 2026.
Oct 2026PR NewswireNews article
Halia Therapeutics presents at the **Morgan Stanley 24th Annual Global Healthcare Conference** in New York City. The clinical-stage biopharmaceutical company focuses on developing first-in-class therapies targeting inflammasome-driven diseases. The event runs from **September 14–16, 2026**, offering a platform for Halia to showcase its pipeline to investors and industry experts.
Sep 2026PR NewswireNews article
Halia Therapeutics presents preclinical and clinical data on **HT-4253**, a candidate for Alzheimer’s prevention in **APOE4 carriers**. Early studies show the drug reduces neuroinflammation and tau pathology. A second poster details a **Phase 2a biomarker trial** in pre-symptomatic individuals, leveraging genomics screening from the **UAE**.
Jul 2026PR NewswireNews article
The UAE initiates the first genomics-driven clinical trial to prevent Alzheimer’s disease, leveraging the Emirati Genome Programme. Researchers identify high-risk individuals based on genetic data before symptoms emerge. The trial aims to intervene early using genomic insights to mitigate disease progression.
Jun 2026PharmaTimesNews article